Advertisement
BRKR vs ILMN
Which Stock Would AI Choose? Bruker Corporation (BRKR) vs. Illumina, Inc. (ILMN) Stock Comparison
Key Takeaways
- Illumina (ILMN) delivered a robust one-year return of approximately 66%, significantly outpacing Bruker Corporation (BRKR)'s 6% gain.
- BRKR leads year-to-date (YTD) performance with a 22% rise, compared to ILMN's 2% increase, amid recent product launches.
- Both stocks operate in the life sciences tools sector, but ILMN boasts a larger market capitalization of $19.5 billion versus BRKR's $5.6 billion.
- ILMN reports positive trailing twelve-month (TTM) earnings per share (EPS) of $5.45, while BRKR shows negative EPS of -$0.15.
- Recent weeks feature innovation catalysts for both, including BRKR's spatial biology tools and ILMN's genomics partnerships.
- ILMN exhibits lower price-to-earnings (P/E) ratio at 23.6 versus BRKR's 74.9, suggesting relative valuation differences.
Introduction
Bruker Corporation (BRKR) and Illumina, Inc. (ILMN) represent key players in the life sciences instrumentation sector, providing tools essential for research in pharmaceuticals, biotechnology, and diagnostics. This stock comparison analyzes their recent market performance, business drivers, and relative positioning, offering insights for investors focused on healthcare innovation and growth-oriented equities. Traders monitoring sector momentum or seeking exposure to genomics and analytical technologies may find value in evaluating these stocks' trajectories amid evolving market conditions.
BRKR Overview and Recent Performance
Bruker Corporation (BRKR) develops high-performance scientific instruments, including mass spectrometry, nuclear magnetic resonance (NMR), and X-ray systems, serving life sciences, pharma, and materials research markets. Shares recently traded around $36.53, with a market cap of $5.6 billion. In recent market activity, BRKR has shown volatility, posting YTD gains of 22% but modest one-year returns of 6%. Sentiment has been influenced by Q4 2025 earnings, where revenue beat estimates but EPS missed, alongside product unveilings at conferences like AACR 2026 and ESCMID 2026, including spatial biology workflows and the MyGenius PRO molecular diagnostics system. Upcoming Q1 2026 earnings add anticipation, though shares have faced pressure from broader sector dynamics.
ILMN Overview and Recent Performance
Illumina, Inc. (ILMN) is a leader in DNA sequencing and array-based solutions for genetic analysis, enabling advancements in genomics, oncology, and personalized medicine. The stock recently closed near $128.52, supported by a $19.5 billion market cap. Recent performance highlights one-year returns of 66%, though YTD up only 2%, reflecting sustained momentum from strong Q4 FY2025 results where EPS beat expectations. Key developments include expanded partnerships, such as with Labcorp for precision oncology next-generation sequencing (NGS) and initiatives in pediatric genomics, alongside software updates like DRAGEN v4.5. These factors have bolstered investor sentiment amid upcoming Q1 earnings.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curating 25 elite selections from a total of 351 bots that collectively trade thousands of tickers across diverse market conditions. These bots employ varied strategies, including AI Trading Signal Agents for pattern recognition, Virtual Agents for simulated trading, and Brokerage Agents for automated execution, spanning timeframes from day trading to swing positions. Performance metrics vary, with top bots often displaying win rates above 60%, average annual returns in the 20-50% range, and thousands of historical trades analyzed for reliability. While specific bots may target life sciences tickers like BRKR or ILMN, the selection emphasizes adaptability to current volatility. Explore Tickeron’s full suite to identify bots aligning with your trading style.
Head-to-Head Comparison
Bruker (BRKR) and Illumina (ILMN) both cater to life sciences research but differ in focus: BRKR offers broad analytical instruments, while ILMN specializes in sequencing platforms. Growth drivers include BRKR's multi-omics tools versus ILMN's genomics dominance. Recent momentum favors ILMN with superior one-year gains, though BRKR edges YTD amid product catalysts. Risk profiles show both with betas above 1.0 (1.20 for BRKR, 1.45 implied for ILMN), but BRKR's negative EPS signals higher volatility. Sector exposure overlaps in biotech tools, yet ILMN benefits from stronger profitability (19.6% margins) and partnerships, contrasting BRKR's revenue beats but earnings challenges. Market sentiment tilts toward ILMN's stability.
Tickeron AI Verdict
Tickeron’s AI currently leans toward Illumina (ILMN) based on trend consistency, positive profitability, and relative strength in one-year performance amid genomics tailwinds. While BRKR offers YTD outperformance and innovation potential, its earnings volatility and negative EPS temper positioning. This probabilistic edge for ILMN reflects observable catalysts like partnerships, though both warrant monitoring for earnings updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BRKR is a StrongBuy and ILMN is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BRKR’s FA Score shows that 1 FA rating(s) are green whileILMN’s FA Score has 3 green FA rating(s).
- BRKR’s FA Score: 1 green, 4 red.
- ILMN’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BRKR’s TA Score shows that 5 TA indicator(s) are bullish while ILMN’s TA Score has 2 bullish TA indicator(s).
- BRKR’s TA Score: 5 bullish, 4 bearish.
- ILMN’s TA Score: 2 bullish, 6 bearish.
Price Growth
BRKR (@Medical/Nursing Services) experienced а -0.09% price change this week, while ILMN (@Medical Specialties) price change was -3.30% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.22%. For the same industry, the average monthly price growth was -3.84%, and the average quarterly price growth was -16.30%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.45%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was -3.19%.
Reported Earning Dates
BRKR is expected to report earnings on Aug 05, 2026.
ILMN is expected to report earnings on Aug 12, 2026.
Industries' Descriptions
@Medical/Nursing Services (-0.22% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+0.45% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BRKR | ILMN | BRKR / ILMN | |
| Capitalization | 8.39B | 25B | 34% |
| EBITDA | 306M | 1.43B | 21% |
| Gain YTD | 20.281 | 23.041 | 88% |
| P/E Ratio | 74.88 | 29.34 | 255% |
| Revenue | 3.46B | 4.39B | 79% |
| Total Cash | N/A | 1.16B | - |
| Total Debt | 1.67B | 2.54B | 66% |
BRKR | ILMN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 85 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 49 Fair valued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 30 | |
PRICE GROWTH RATING 1..100 | 37 | 11 | |
P/E GROWTH RATING 1..100 | 5 | 7 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BRKR's Valuation (49) in the Medical Specialties industry is in the same range as ILMN (75) in the Biotechnology industry. This means that BRKR’s stock grew similarly to ILMN’s over the last 12 months.
BRKR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ILMN (100) in the Biotechnology industry. This means that BRKR’s stock grew similarly to ILMN’s over the last 12 months.
ILMN's SMR Rating (30) in the Biotechnology industry is somewhat better than the same rating for BRKR (92) in the Medical Specialties industry. This means that ILMN’s stock grew somewhat faster than BRKR’s over the last 12 months.
ILMN's Price Growth Rating (11) in the Biotechnology industry is in the same range as BRKR (37) in the Medical Specialties industry. This means that ILMN’s stock grew similarly to BRKR’s over the last 12 months.
BRKR's P/E Growth Rating (5) in the Medical Specialties industry is in the same range as ILMN (7) in the Biotechnology industry. This means that BRKR’s stock grew similarly to ILMN’s over the last 12 months.
| BRKR | ILMN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 55% | 2 days ago 71% |
| Stochastic ODDS (%) | 2 days ago 67% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 68% | 2 days ago 78% |
| MACD ODDS (%) | 2 days ago 63% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 71% | 2 days ago 68% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 73% |
| Advances ODDS (%) | 26 days ago 69% | 13 days ago 70% |
| Declines ODDS (%) | 7 days ago 72% | 7 days ago 79% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 61% | 2 days ago 81% |
Advertisement
BRKR and
Correlation & Price change
A.I.dvisor indicates that over the last year, BRKR has been closely correlated with A. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if BRKR jumps, then A could also see price increases.
| Ticker / NAME | Correlation To BRKR | 1D Price Change % | ||
|---|---|---|---|---|
| BRKR | 100% | -1.14% | ||
| A - BRKR | 78% Closely correlated | -0.45% | ||
| MTD - BRKR | 75% Closely correlated | +1.68% | ||
| WAT - BRKR | 68% Closely correlated | +0.79% | ||
| RVTY - BRKR | 68% Closely correlated | -0.96% | ||
| TMO - BRKR | 66% Loosely correlated | -0.13% | ||
More | ||||
ILMN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ILMN has been loosely correlated with BRKR. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ILMN jumps, then BRKR could also see price increases.
| Ticker / NAME | Correlation To ILMN | 1D Price Change % | ||
|---|---|---|---|---|
| ILMN | 100% | -0.34% | ||
| BRKR - ILMN | 60% Loosely correlated | -1.14% | ||
| RVTY - ILMN | 58% Loosely correlated | -0.96% | ||
| AZTA - ILMN | 51% Loosely correlated | -4.46% | ||
| BIO - ILMN | 50% Loosely correlated | -0.47% | ||
| A - ILMN | 50% Loosely correlated | -0.45% | ||
More | ||||